Counteracting the Disease Continuum in Hormone-Sensitive Prostate Cancer
Tweetorial #1 References

Tweet 3

SEER*Explorer. An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed August 12, 2021. https://seer.cancer.gov/explorer/

SEER. Cancer stat facts: prostate cancer. National Cancer Institute. Bethesda, MD. Accessed August 12, 2021. https://seer.cancer.gov/statfacts/html/prost.html

Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. *Nat Rev Dis Primers*. Feb 4 2021;7(1):9. doi:10.1038/s41572-020-00243-0

Tweet 4

Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. *Nat Rev Dis Primers*. Feb 4 2021;7(1):9. doi:10.1038/s41572-020-00243-0

Tweet 5

Svensson J, Lissbrant IF, Gauffin O, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. *Scand J Urol*. Feb 2021;55(1):1-8. doi:10.1080/21681805.2020.1851762

Tweet 7

Svensson J, Lissbrant IF, Gauffin O, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. *Scand J Urol*. Feb 2021;55(1):1-8. doi:10.1080/21681805.2020.1851762

Lowrance WT, Breau RH, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. *J Urol*. Jan 2021;205(1):14-21. doi:10.1097/JU.0000000000001375

Tweet 8

Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. *Eur Urol*. Feb 2021;79(2):243-262. doi:10.1016/j.eururo.2020.09.042

Tweet 9

Fu AZ, Tsai HT, Haque R, et al. Mortality and androgen deprivation therapy as salvage treatment for biochemical recurrence after primary therapy for clinically localized prostate cancer. *J Urol*. Jun 2017;197(6):1448-1454. doi:10.1016/j.juro.2016.12.086

Garcia-Albeniz X, Chan JM, Paciorek A, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. *Eur J Cancer*. May 2015;51(7):817-24. doi:10.1016/j.ejca.2015.03.003

Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. *Lancet Oncol*. Jun 2016;17(6):727-737. doi:10.1016/S1470-2045(16)00107-8

Tweet 10

Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. *N Engl J Med*. Sep 6 2012;367(10):895-903. doi:10.1056/NEJMoa1201546

Casas F, Henriquez I, Bejar A, et al. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study. *Clin Transl Oncol*. Mar 2017;19(3):373-378. doi:10.1007/s12094-016-1538-5

Tweet 11

Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. *The Lancet Oncology*. 2019;20(9):1286-1294. doi:10.1016/s1470-2045(19)30415-2

Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. *JAMA Oncol*. May 1 2020;6(5):650-659. doi:10.1001/jamaoncol.2020.0147

Tweet 12

Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. *N Engl J Med*. 2019;381:13-24.

Chi KN, Chowdhury S, Bjartell A, et al. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Accessed March 11, 2021. doi:10.1200/JCO.2021.39.6_suppl.11

Agarwal N, McQuarrie K, Bjartell A, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. *Lancet Oncol*. 2019;20:1518-1530.

Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med*. 2018;378:1408-1418.

Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2019;380:1235-1246.

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. *N Engl J Med*. 2019;381:121-131.

Armstrong AJ, Szmuelwitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. *J Clin Oncol*. 2019;37:2974-2986.

Wallis CJD. ESMO 2021: Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide + ADT in Men With mHSPC. Accessed September 21, 2021. https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-prostate-cancer/132209-esmo-2021-lba25-final-overall-survival-os-analysis-from-arches-a-phase-3-randomized-double-blind-placebo-pbo-controlled-study-of-enzalutamide-enza-androgen-deprivation-therapy-adt-in-men-with-metastatic-hormone-sensitive-prostate-cancer-mhspc.html

Hussein M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer*. N Engl J Med*. 2018;378:2465-2474.

Tweet 13

Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. *Nat Rev Dis Primers*. Feb 4 2021;7(1):9. doi:10.1038/s41572-020-00243-0

ClinicalTrials.gov. A study of androgen annihilation in high-risk biochemically relapsed prostate cancer. NCT03009981. Updated January 4, 2017. Accessed August 31, 2021. https://clinicaltrials.gov/ct2/show/study/NCT03009981

ClinicalTrials.gov. A study of adding apalutamide to radiotherapy and lhrh agonist in high-risk patients with prostate-specific membrane antigen-positron emission tomography (PSMA-PET) positive hormone-sensitive prostate cancer participants (PRIMORDIUM). NCT04557059. Updated: July 23, 2021. Accessed August 17, 2021. https://clinicaltrials.gov/ct2/show/NCT04557059

Hadaschik BA, Fanti S, Ost P, et al. 649TiP - PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer. *Ann Oncol*. 2021;32(suppl_5):S626-S677. doi:10.1016/annonc/annonc702

ClinicalTrials.gov. Safety and efficacy study of enzalutamide plus leuprolide in patients with nonmetastatic prostate cancer (EMBARK). NCT02319837. Updated: April 23, 2021. Accessed August 17, 2021. https://clinicaltrials.gov/ct2/show/NCT02319837?term=NCT02319837&draw=2&rank=1

Tweet 15

Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *N Engl J Med*. 1998;339(15):1036-1042. doi:10.1056/NEJM199810083391504

Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. *J Clin Oncol*. 2008;26(36):5936-5942. doi:10.1200/JCO.2007.15.9830

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *N Engl J Med*. 2015;373(8):737-46. doi:10.1056/NEJMoa1503747

Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. *J Clin Oncol*. 2018;36(11):1080-1087. doi:10.1200/JCO.2017.75.3657

Fizazi K, Shore ND, Tammela T, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). *J Clin Oncol*. 2019;37(7_suppl):140-140. doi:10.1200/JCO.2019.37.7_suppl.140

Ali A, Hoyle A, Haran AM, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. *JAMA Oncol*. 2021;7(4):555-563. doi:10.1001/jamaoncol.2020.7857

Tweet 16

ClinicalTrials.gov. ODM-201 in addition to standard ADT and docetaxel in metastatic castration sensitive prostate cancer (ARASENS). Updated: July 29, 2021. Accessed August 17, 2021. https://www.clinicaltrials.gov/ct2/show/NCT02799602?term=NCT02799602&draw=2&rank=1

ClinicalTrials.gov. A phase III study for patients with metastatic hormone-naïve prostate cancer (PEACE1). Updated: May 5, 2021. Accessed August 17, 2021. https://www.clinicaltrials.gov/ct2/show/NCT01957436?term=NCT01957436&draw=2&rank=1

Berchuck J. ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1. Accessed September 21, 2021. https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-prostate-cancer/132237-esmo-2021-a-phase-3-trial-with-a-2x2-factorial-design-in-men-with-de-novo-metastatic-castration-sensitive-prostate-cancer-overall-survival-with-abiraterone-acetate-plus-prednisone-in-peace-1.html

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-Line therapy in metastatic prostate cancer. *N Engl J Med*. 2019;381(2):121-131. doi:10.1056/NEJMoa1903835

Tweet 17

Sweeney CJ, Beltran H. The balancing act: assessing treatment burden versus treatment benefit with evolving metastatic hormone-sensitive prostate cancer data. *Eur Urol*. 2019;76(6):729-731. doi:10.1016/j.eururo.2019.09.017

Sweeney CJ, Martin AJ, Stockler MR, et al. Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. *Eur Urol*. 2021;80(3):275-279. doi:10.1016/j.eururo.2021.05.016

Tweet 18

ClinicalTrials.gov. ODM-201 in addition to standard ADT and docetaxel in metastatic castration sensitive prostate cancer (ARASENS). Updated: July 29, 2021. Accessed August 17, 2021. https://www.clinicaltrials.gov/ct2/show/NCT02799602?term=NCT02799602&draw=2&rank=1

ClinicalTrials.gov. A phase III study for patients with metastatic hormone-naïve prostate cancer (PEACE1). Updated: May 5, 2021. Accessed August 17, 2021. https://www.clinicaltrials.gov/ct2/show/NCT01957436?term=NCT01957436&draw=2&rank=1

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-Line therapy in metastatic prostate cancer. *N Engl J Med*. 2019;381(2):121-131. doi:10.1056/NEJMoa1903835

Glossary

AAP, abiraterone acetate plus prednisolone
ABI, abiraterone
ADT, androgen deprivation therapy
AEs, adverse events
ALT, alanine transaminase
APA, apalutamide
AR, androgen receptor
BCR, biochemical relapse
BS, bone scintigraphy
CAD, continuous androgen deprivation
CI, confidence interval
cN+, clinically node positive
CrCl, creatinine clearance
CRFS, castration resistance-free survival
CT, computed tomography
CT A/P, computed tomography of the abdomen and pelvis
cT, clinical tumor stage
DAR, darolutamide
DOC, docetaxel
EBRT, external beam radiation therapy
ENZ, enzalutamide
Gen, generation
GS, Gleason score
Hb, hemoglobin
HR, hazard ratio
HSPC, hormone-sensitive prostate cancer
HV, high volume
IAD, intermittent androgen-deprivation
ISUP, International Society of Urological Pathology
LA, locally advanced
LEU, leuprolide
LHRHa, luteinizing hormone releasing hormone analog
LN, lymph node
LV, low volume
M, metastases
MACE, major adverse cardiovascular events
mCRPC, metastatic castration-resistant prostate cancer
Metach, metachronous
Mets, metastases
MFS, metastasis-free survival
mHSPC, metastatic hormone-sensitive prostate cancer
mOS, median overall survival

mMFS, median MFS
MSK, musculoskeletal
N, nodes
nmCRPC, nonmetastatic castration-resistant prostate cancer
nmHSPC, nonmetastatic hormone-sensitive prostate cancer
NRLN, nonregional lymph node
OS, overall survival
PBO, placebo
PCa, prostate cancer
PE, primary endpoint
PET, positron emission tomography
PFS, progression-free survival
PLND, pelvic lymph node dissection
ppMPFS, PSMA-PET metastatic-free survival
PSA, prostate specific androgen
PSADT, PSA doubling time
PSMA, prostate-specific membrane antigen
QOL, quality of life
RP, radical prostatectomy
rPSF, radiographic PFS
RT, radiation therapy
SE, secondary endpoint
SBRT, stereotactic body radiation therapy
SOC, standard of care
SRT, salvage radiation therapy
Synch, synchronous
T, tumor
Testo, testosterone
TNM, Tumor, Node, Metastasis
TTR, time to relapse
TTST, time to subsequent therapy
ULN, upper limit of normal
WCC, white cell count